Know Cancer

forgot password

At Home Evaluation of Two Pneumatic Compression Devices in the Treatment of Lower Extremity Lymphoedema(ACE: At Home Compression Evaluation)

Phase 4
18 Years
Open (Enrolling)

Thank you

Trial Information

At Home Evaluation of Two Pneumatic Compression Devices in the Treatment of Lower Extremity Lymphoedema(ACE: At Home Compression Evaluation)

This is a Multicentre, prospective, single (assessor) blind randomised study. The primary
objective of the study is to assess volume reduction in the treatment of lymphoedematous
legs with an advanced PCD compared to a simple PCD in patients with lower limb lymphoedema.
The main outcome is the percentage volume reduction of the affected limb at end of treatment
compared to baseline.

Secondary objectives of the study are Assessment of safety Quality of life Health economic

In total 262 patients with leg lymphoedema will be enrolled into the study. Patients
eligible for the study are those who suffer from late stage II and stage III according to
the International Society of Lymphology lymphoedema staging. Lymphoedematous legs can be of
primary or secondary origin and uni or bilaterally affected. Medical history will be taken
at baseline.

Patients will be taught how to use the device they have been randomised to. Visits will then
take place at weeks 1,4,8,12 and 24 weeks. The device will be used for up to 60 minutes each
day on the trial limb. At each visit sequential circumferences of the affected and
unaffected limbs will be measured with a tape measure.

All adverse events will be documented. At beginning and end of study quality of life
questionnaires and health economic information will be completed by the patients.

At the Derby site assessment of tissue quality will be made using ultrasound and moisture
meter to assess tissue fluid.

Inclusion Criteria:

- Subjects must be ≥ 18 years old or legal age in host country.

- Subjects must have a diagnosis of primary or secondary late Stage 2 or 3 unilateral
or bilateral lower extremity lymphoedema.

- At time of initial evaluation, individuals must be at least 3 months post-surgery,
chemotherapy and/or radiation treatment for cancer if applicable.

- If subjects were treated in a clinic setting for lymphoedema (Phase 1 treatment) they
must be at least 3 months post completion of their acute care.

Exclusion Criteria:

- Diagnosis of active or recurrent cancer, or less than 3 months at the time of initial
evaluation from the completion of chemotherapy, radiation therapy or primary surgery
for the treatment of cancer.

- Diagnosis of acute infection. The source of the infection must be treated for 2 weeks
prior to admittance into the study.

- Diagnosis of acute thrombophlebitis (in last 2 months)

- Diagnosis of peripheral arterial disease (PAD): PAD is defined as an Ankle Brachial
Index (ABI), of 0.7 or lower.

- Diagnosis of pulmonary embolism or deep vein thrombosis within the previous 6 months

- Diagnosis of pulmonary edema

- Diagnosis of congestive heart failure (uncontrolled)

- Diagnosis of chronic kidney disease with a Glomerular Filtration Rate (GFR) of less
than 30 mls per minute.

- Patients with poorly controlled asthma (i.e. those with severe persistent symptoms
throughout the day, night time awakenings several times per week, use of a beta2
agonist inhaler several times per day and those whose normal activity is extremely

- Pregnancy

- Any condition where increased venous and lymphatic return is undesirable

- Inability or unwillingness to participate in all aspects of study protocol and/or
inability to provide informed consent

- Currently participating in another clinical trial

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

limb volume change after 12 weeks of treatment

Outcome Description:

Limb volume as assessed by tape measure at 4 cm intervals up the limb. Volume calculated by assuming a truncated cone for each section of the limb.

Outcome Time Frame:

12 weeks

Safety Issue:


Principal Investigator

Christine J Moffatt, RN PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Centre for Research & Implementation of Clinical Practice


United Kingdom: Medicines and Healthcare Products Regulatory Agency

Study ID:

Flexitouch 1010



Start Date:

November 2010

Completion Date:

December 2013

Related Keywords:

  • Lymphedema
  • lymphedema
  • pneumatic compression device
  • randomised clinical trial
  • volume reduction
  • Lymphedema



University of Pittsburgh Medical CenterPittsburgh, Pennsylvania  15213
Northwestern UniversityChicago, Illinois  60611
Ohio State University Medical CenterColumbus, Ohio  43210
Stony Brook University Medical CenterStony Brook, New York  11794
Hope Research InstitutePhoenix, Arizona  
Greenville Hospital SystemsGreenville, South Carolina  
Prairie Education & Research CooperativeSpringfield, Illinois  62701
University of Missouri-Columbia,Ellis Fischel Cancer Center, Lymphedema Therapy ClinicColumbia, Missouri  65203
Carolinas RehabilitationCharlotte, North Carolina  
Fletcher Allen Health Care, Inc., University of VermontColchester, Vermont  05446